Abstract

We aimed to validate quantitative high-resolution computed tomography (HRCT) imaging analyses of interstitial lung disease (ILD) in rheumatoid arthritis (RA) patients, and to delineate a broad spectrum of annual longitudinal changes of ILD severity in the RA-ILD cohorts. Retrospective cohort 1 (n = 26) had matched PFT results and prospective cohort 2 (n = 34) were followed for over two years with baseline serum specimen. Automated quantitative analysis of HRCT was expressed as the extent of ground-glass opacity, lung fibrosis, honeycombing, and their summation—the total extent of quantitative ILD (QILD). Higher QILD score was associated with lower pulmonary function especially for DLCO% (ρ = −0.433, p = 0.027). Higher serum level of Krebs von den Lungen 6 were significantly associated with high QILD scores (ρ = 0.400, p = 0.026). Regarding QILD score changes in whole lung, even a single point increase was significantly associated with interval progression detected by the radiologist. Four distinct patterns (improvement, worsening, convex-like, and concave-like) during the 24 months were described by QILD scores. Prolonged disease duration of ILD at baseline was significantly associated with worsening of QILD scores. QILD has the potential to reliably evaluate the dynamic severity changes in patients with RA-ILD.

Highlights

  • Rheumatoid arthritis (RA) is a systemic inflammatory disease mainly characterized by chronic inflammatory synovitis

  • A total of 159 high-resolution computed tomography (HRCT) were longitudinally obtained from two independent cohorts of RA patients with Interstitial lung disease (ILD) (n = 60)

  • When we focused on the zone of the maximal involvement, forced vital capacity (FVC)% had significant negative and positive correlation with quantitative ILD (QILD) score and zonal volume, respectively (Figure S1B)

Read more

Summary

Introduction

Rheumatoid arthritis (RA) is a systemic inflammatory disease mainly characterized by chronic inflammatory synovitis. Detecting ILD and evaluating its changes in RA patients would be important in improving their treatment outcome. Determining screening frequency and follow-up method for subclinical ILD in RA can be difficult. Another challenge in managing RA-ILD is the lack of definite treatment option other than considering the cessation of harmful disease modifying antirheumatic drugs (DMARDs) with definitive pulmonary toxicity such as leflunomide [4]. Mycophenolate mofetil (MMF) had a promising effect by showing stable or improved pulmonary functions [7]. The use of other drugs such as abatacept (NCT03084419), tofacitinib (NCT04311567), pirfenidone (NCT02808871), and nintedanib (NCT02999178) are under clinical trial to improve the outcome of RA-ILD

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call